

PTO/SB/25(09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTI	ING Docket Number (Optional)
REJECTION OVER A PENDING "REFERENCE" APPLICATION	20269/1201776-US2
In re Application of: Jay D. Kranzler et al.	
Application No.: 10/623,431	
Filed: July 18, 2003	
For: METHODS OF TREATING FIBROMYALGIA SYNDROME, CHRC AND PAIN	ONIC FATIGUE SYNDROME
The owner*, Cypress Bioscience, Inc.  percent interest in the instant application hereby disclaims, except as provided below, the any patent granted on the instant application which would extend beyond the expiration da patent granted on pending reference Application Number 10/623,378, filed on as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted be shortened by any terminal disclaimer filed prior to the grant of any patent on the pendin hereby agrees that any patent so granted on the instant application shall be enforceable of and the patent granted on the reference application are commonly owned. This agreems the instant application and is binding upon the grantee, its successors or assigns.  In making the above disclaimer, the owner does not disclaim the terminal part of application that would extend to the expiration date of the full statutory term as defined in a granted on said reference application, "as the term of any patent granted on said reference application. Ference application are commonly owned.	late of the full statutory term of any n July 18, 2003 , ed on said reference application may ing reference application. The owner only for and during such period that it ment runs with any patent granted on of any patent granted on the instant a 35 U.S.C. 154 and 173 of any patent since application may be shortened by oplication," in the event that: any such
patent: granted on the pending reference application: expires for failure to pay a mainte found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or t 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any man of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	terminally disclaimed under 37 CFR
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. X The undersigned is an attorned or agent of record. Reg. No. 52,	2,392
- das Milaso	June 10, 2005
Signature	Date
Paul M. Zagar, M.D.	
Typed or printed name	1040) 507 7770
•	(212) 527-7770 Telephone Number
<u> </u>	Total Talles
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assigned Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	nee (owner).
THE PUE ONN	000020 10623431
06/15/2005 MBERHE 0000	130.00 OP
04 FC:1814	100100